Effectiveness of KOS-862 in the Treatment of Lung Cancer

• Status: Terminated
• Trial end date: 2004-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior platinum-containing chemotherapy regimen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Desoxyepothilone B

Criteria

Inclusion Criteria:

• At least 18 years of age

• Measurable disease

• One previous treatment of a platinum based drug such as cisplatin or carboplatin

• At least 3 weeks since last surgery/radiation/chemotherapy

Exclusion Criteria:

• Brain metastases

• Changes in the rhythm of your heart that are considered significant as determined by an ECG tracing